Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors
Cancer Discovery · 2023
DOI: 10.1158/2159-8290.cd-23-0199 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer Discovery, 2023. Verfasst von Michael Dougan. Beteiligte Einrichtung: Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Myocarditis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
In this issue of Cancer Discovery, Salem and colleagues report a combination therapy for immune-checkpoint inhibitor (ICI) myocarditis using high-dose glucocorticoids, abatacept, and the JAK inhibitor ruxolitinib. The apparent efficacy of their strategy and an accompanying animal model provide further evidence for common immune mechanisms underlying ICI toxicities. See related article by Salem et al., p. 1100 (2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Michael Dougan
Zitieren
APA
Dougan, M. (2023). Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0199
Vancouver
Dougan M. Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors. Cancer Discovery. 2023. doi:10.1158/2159-8290.cd-23-0199
BibTeX
@article{Dougan2023,
author = {Dougan, Michael},
title = {Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors},
journal = {Cancer Discovery},
year = {2023},
doi = {10.1158/2159-8290.cd-23-0199}
}
EUVIMED